Alira Health and GDMH together to boost Life Sciences innovation

The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.

Alira Health, a global advisory and clinical research firm with the mission to humanize healthcare and life sciences, announces a new collaboration agreement signed with GDMH – Gemelli Digital Medicine & Health, part of Fondazione Policlinico Agostino Gemelli IRCCS (FPG) and prime provider of turn-key solutions in digital medicine and health in Italy. The goal of this partnership is to develop innovative solutions in the fields of Digital Health, Real-World Evidence (RWE) and Market Access in the best interest of research and patients, while ensuring the highest standards of data quality and protection.

We are thrilled to kick start this partnership with GDMH to accelerate the adoption of patient-centered technologies in our quest to humanize healthcare. We are joining forces with GDMH to build, in partnership with patients, digital health solutions that enable a full spectrum of use cases, including Decentralized Clinical Trials, Patient Support Programs, and DTx for pharma, MedTech, providers, and the payer community. Together GDMH and Alira Health bring a wealth of knowledge in clinical development, health tech, data science, market access, commercial strategy, and RWE.”
Piergiulio Lauriano Chief Strategy Officer at Alira Health
We at GDMH look forward to this collaboration in order to bring our digital solutions closer to the clinical research domain in a pragmatic and efficient way. It will help deepen each party's capabilities and bring lessons and solutions to GDMH, the healthcare and Pharma industries, as well as to the medical community and patients, and possibly to other industry sectors.”
Alfredo Cesario Chief Executive Officer at GDMH
Alira Health and GDMH will collaborate together in the fields of Digital Health, RWE and Market Access to co-develop innovative solutions in the best interests of research and patients. Thanks to this partnership, we will be able to merge our know-how, network, and capabilities, to explore the use of innovative digital health solutions and enable a full spectrum of use cases of joint value for both GDMH and Alira Health.”
Jean-François Ricci Chief Access Officer at Alira Health
About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

Learn more:

About GDMH – Gemelli Digital Medicine & Health

Gemelli Digital Medicine & Health (GDMH), a company fully owned by Fondazione Policlinico Gemelli, is a prime integrator and provider of turn-key solutions in Digital Medicine and Health. First movers in the market with the profile of a large general hospital spin off we co-create together with the best players in the Digital Medicine scenario, deploy and manage advanced digital medical solutions worldwide with complete ethical, technical, and legal credentials.

Learn more:

Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events August 10, 2023
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
EU Market Access
Events July 31, 2023
ESMO Congress
We are excited to join the ESMO Congress in Madrid. to disseminate the latest cutting-edge data for oncologists and other stakeholders.
Drug Development Market Access Oncology Spain
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.